Overview
WHWK market data
Price History
WHWK price chart · 1M
- O
- 4.90
- H
- 4.97
- L
- 4.87
- C
- 4.87
- Vol
- 61,741.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $4.90
- Previous Close
- $4.83
- Day High
- $4.97
- Day Low
- $4.87
- 52 Week High
- $5.48
- 52 Week Low
- $3.41
- 7 Day Return
- +1.04%
- 30 Day Return
- +32.52%
- 90 Day Return
- +3.18%
- 1 Year Return
- +20.84%
- Daily Notional Volume
- $300.7K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.44 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.95 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 99.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.70 – $5.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $253.3M · P/B 0.84 · P/S 9.12.
Company News
8-K filing — Whitehawk Therapeutics, Inc. (WHWK)SEC EDGAR · Aug 6, 2026, 2:08 PM
Whitehawk Therapeutics Q2 EPS $(0.20) Beats $(0.30) EstimateBenzinga · Aug 6, 2026, 12:46 PM
Leerink Partners Initiates Coverage On Whitehawk Therapeutics with Outperform Rating, Announces Price Target of $9Benzinga · Jul 13, 2026, 5:55 PM
Whitehawk Therapeutics Collaborates With Biocytogen To Develop Bispecific Antibody-Drug ConjugatesBenzinga · Jul 7, 2026, 12:10 PM
Whitehawk Therapeutics Files Prospectus For Resale Of 22,321,887 Shares Of Common StockBenzinga · May 29, 2026, 8:25 PM